Robin Osterhout

3.8k total citations · 2 hit papers
17 papers, 2.8k citations indexed

About

Robin Osterhout is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Robin Osterhout has authored 17 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Robin Osterhout's work include Microbial Metabolic Engineering and Bioproduction (5 papers), Enzyme Catalysis and Immobilization (3 papers) and Biofuel production and bioconversion (3 papers). Robin Osterhout is often cited by papers focused on Microbial Metabolic Engineering and Bioproduction (5 papers), Enzyme Catalysis and Immobilization (3 papers) and Biofuel production and bioconversion (3 papers). Robin Osterhout collaborates with scholars based in United States, Germany and Moldova. Robin Osterhout's co-authors include Stephen J. Van Dien, Melissa Gao, Joshua D. Rabinowitz, Elizabeth Kimball, Bryson D. Bennett, Anthony P. Burgard, Harry Yim, Mark J. Burk, Stephen Van Dien and Tae Hoon Yang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Langmuir.

In The Last Decade

Robin Osterhout

16 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli

2009 1.4k citations Bryson D. Bennett, Elizabeth Kimball et al. Nature Chemical Biology profile →
Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol

2011 857 citations Harry Yim, Robert J. Haselbeck et al. Nature Chemical Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Osterhout United States	12	2.2k	761	354	286	175	17	2.8k
Nalam Madhusudhana Rao India	29	1.9k 0.9×	350 0.5×	386 1.1×	248 0.9×	213 1.2×	87	2.4k
David Bednář Czechia	32	2.4k 1.1×	439 0.6×	130 0.4×	527 1.8×	335 1.9×	96	3.4k
Radka Chaloupková Czechia	30	2.6k 1.2×	481 0.6×	145 0.4×	785 2.7×	107 0.6×	93	3.4k
Michael M. Domach United States	23	1.2k 0.6×	436 0.6×	325 0.9×	161 0.6×	64 0.4×	70	1.8k
Jaap Kingma Netherlands	30	2.0k 0.9×	244 0.3×	424 1.2×	311 1.1×	373 2.1×	39	2.9k
Zhonghu Bai China	23	2.1k 0.9×	420 0.6×	272 0.8×	92 0.3×	89 0.5×	105	3.4k
Haiyan Wang China	30	2.0k 0.9×	874 1.1×	83 0.2×	555 1.9×	103 0.6×	156	2.9k
Shuang Fu China	25	1.7k 0.8×	433 0.6×	194 0.5×	565 2.0×	246 1.4×	88	2.9k
Rolandas Meškys Lithuania	25	1.2k 0.6×	279 0.4×	112 0.3×	215 0.8×	75 0.4×	160	2.5k
Neela H. Yennawar United States	25	1.1k 0.5×	233 0.3×	119 0.3×	315 1.1×	85 0.5×	68	1.9k

Countries citing papers authored by Robin Osterhout

Since Specialization

Citations

This map shows the geographic impact of Robin Osterhout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Osterhout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Osterhout more than expected).

Fields of papers citing papers by Robin Osterhout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Osterhout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Osterhout. The network helps show where Robin Osterhout may publish in the future.

Co-authorship network of co-authors of Robin Osterhout

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Osterhout. A scholar is included among the top collaborators of Robin Osterhout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Osterhout. Robin Osterhout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Ghofrani, Hossein Ardeschir, Robin Osterhout, Raymond L. Benza, et al.. (2024). TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment. A7383–A7383.

Pullamsetti, Soni Savai, Ravikumar Sitapara, Robin Osterhout, et al.. (2023). Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 24(16). 12653–12653. 11 indexed citations

Liu, Xiuting, Graham D. Hogg, Chong Zuo, et al.. (2023). Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 41(6). 1073–1090.e12. 53 indexed citations

Moss, Mark H., Njira Lugogo, Mario Castro, et al.. (2022). Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. CHEST Journal. 162(2). 297–308. 5 indexed citations

Galkin, Anna, Ravikumar Sitapara, Bryan Clemons, et al.. (2022). Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. European Respiratory Journal. 60(6). 2102356–2102356. 49 indexed citations

Osterhout, Robin, et al.. (2022). An orally bioavailable ENPP1-selective inhibitor demonstrates superior immune preservation effects over STING agonists and confers antitumor efficacy in combination with other therapies in syngeneic tumor models. European Journal of Cancer. 174. S125–S125. 4 indexed citations

Danese, Silvio, Barrett G. Levesque, Brian G. Feagan, et al.. (2022). Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics. 55(4). 401–411. 26 indexed citations

Green, Jennifer L., Robin Osterhout, Carsten Merkwirth, et al.. (2021). Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Molecular Therapy — Oncolytics. 23. 547–559. 12 indexed citations

Sandborn, William J., Robin Osterhout, Brian G. Feagan, et al.. (2021). DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis. Journal of Crohn s and Colitis. 15(Supplement_1). S043–S043. 1 indexed citations

10.

Osterhout, Robin, et al.. (2019). Identification of novel targets in non-muscle invasive bladder cancer: A systems biology approach.. Journal of Clinical Oncology. 37(7_suppl). 396–396. 1 indexed citations

11.

Burgard, Anthony P., Mark J. Burk, Robin Osterhout, Stephen Van Dien, & Harry Yim. (2016). Development of a commercial scale process for production of 1,4-butanediol from sugar. Current Opinion in Biotechnology. 42. 118–125. 207 indexed citations

12.

Barton, Nelson, Anthony P. Burgard, Mark J. Burk, et al.. (2014). An integrated biotechnology platform for developing sustainable chemical processes. Journal of Industrial Microbiology & Biotechnology. 42(3). 349–360. 52 indexed citations

13.

Yim, Harry, Robert J. Haselbeck, Wei Niu, et al.. (2011). Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol. Nature Chemical Biology. 7(7). 445–452. 857 indexed citations breakdown →

14.

Yim, Harry, Robert J. Haselbeck, Wei Niu, et al.. (2011). Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol. Nat Chem Biol. 37 indexed citations

15.

Bennett, Bryson D., Elizabeth Kimball, Melissa Gao, et al.. (2009). Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nature Chemical Biology. 5(8). 593–599. 1432 indexed citations breakdown →

16.

Osterhout, Robin, Israel Figueroa, Jay D. Keasling, & Adam P. Arkin. (2007). Global analysis of host response to induction of a latent bacteriophage. BMC Microbiology. 7(1). 82–82. 42 indexed citations

17.

Kurth, Dirk G. & Robin Osterhout. (1999). In Situ Analysis of Metallosupramolecular Coordination Polyelectrolyte Films by Surface Plasmon Resonance Spectroscopy. Langmuir. 15(14). 4842–4846. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact